A Study into GCSF Primary Prophylaxis for Early Breast Cancer Chemotherapy: a Comparative Study from Two Cancer Centres in North London

2017 ◽  
Vol 29 (6) ◽  
pp. e103
Author(s):  
T. Smith ◽  
S. Jenkinson ◽  
F. Raja
Keyword(s):  
Breast Cancer ◽  
Comparative Study ◽  
Early Breast Cancer ◽  
Cancer Chemotherapy ◽  
Primary Prophylaxis ◽  
Breast Cancer Chemotherapy ◽  
North London

The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women.

1993 ◽  
Vol 11 (4) ◽  
pp. 771-776 ◽  
Author(s):  
T J Smith ◽  
B E Hillner
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Cancer Chemotherapy ◽  
Early Stage ◽  
Combined Therapy ◽  
Combined Treatment ◽  
Premenopausal Women ◽  
Cost Effective ◽  
Collaborative Group ◽  
Breast Cancer Chemotherapy

PURPOSE AND METHODS We used decision analysis to model the natural history of breast cancer in hypothetical cohorts of 45-year-old women receiving tamoxifen, chemotherapy, or combined therapy. We used recurrence and efficacy data from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG), utility values from focus groups, and costs from clinic charges and Medicare data. RESULTS Tamoxifen alone provides minimal benefit in estrogen receptor-negative (ER-; 0.2 to 0.4 months) and modest benefit in receptor-positive (ER+; 3.5 to 5.2 months) cancer. Chemotherapy adds substantial benefit independent of receptor status (4.9 to 10.7 quality-adjusted months). In ER+ cancer, combined therapy adds an additional benefit (1.2 to 2.1 months) compared with chemotherapy alone. The incremental costs (United States dollars) necessary to add an additional year of life to the average woman ranged from $4,300 to $11,400 for tamoxifen alone for ER+ cancer, $4,900 to $11,400 for chemotherapy alone, and $14,800 to $33,100 for combined therapy. CONCLUSION In premenopausal early-stage breast cancer, chemotherapy adds substantial clinical benefit at a modest cost. Tamoxifen alone adds meaningful benefit only in ER+ cancer. Combined therapy is effective for all women, but is most beneficial and only cost-effective in ER+ women. If secondary effects of tamoxifen in reduction of cardiovascular and osteoporosis mortality are confirmed, then combined treatment may be optimal for all premenopausal women.

scholarly journals Serum Molecular Signatures of Weight Change during Early Breast Cancer Chemotherapy

2009 ◽  
Vol 15 (21) ◽  
pp. 6716-6723 ◽  
Author(s):  
H. C. Keun ◽  
J. Sidhu ◽  
D. Pchejetski ◽  
J. S. Lewis ◽  
H. Marconell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Cancer Chemotherapy ◽  
Weight Change ◽  
Molecular Signatures ◽  
Breast Cancer Chemotherapy

scholarly journals High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS?

2011 ◽  
Vol 128 (1) ◽  
pp. 273-281 ◽  
Author(s):  
A. C. Regierer ◽  
R. Wolters ◽  
C. Kurzeder ◽  
A. Wöckel ◽  
I. Novopashenny ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Early Breast Cancer ◽  
Cancer Chemotherapy ◽  
Receptor Expression ◽  
Estrogen Receptor Expression ◽  
Breast Cancer Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document